APLS Stock Cash Flow Statements

Apellis Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Apellis Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31

operating activities
net income	-42,151,000	-92,225,000	-36,353,000	-57,445,000	-37,657,000	-66,423,000	-88,576,000	-140,237,000	-122,037,000	-177,778,000	-165,991,000	-191,269,000	-155,977,000	-138,935,000	-147,933,000	-195,571,000	-219,191,000	-183,659,000	78,265,000	-135,700,000	-118,617,000	-168,822,000	-113,217,423	-69,824,659	-71,090,164	-50,574,367	-36,459,474	-35,972,114	-33,334,302	-21,736,304	-18,255,896
adjustments to reconcile net income to net cash from operating activities:
share-based compensation expense	27,197,000	27,374,000	26,314,000	27,475,000	29,990,000	30,349,000	26,219,000	21,625,000	29,278,000	28,823,000	24,241,000	23,541,000	22,530,000	20,773,000	19,312,000	17,194,000	17,722,000	16,439,000	12,494,000	12,099,000	11,489,000	9,294,000	7,107,068	5,295,152	4,183,221	4,558,588	1,828,617	2,050,924	2,243,527	1,610,188	4,164,340
loss on extinguishment of development liability			0	0
depreciation expense	446,000	446,000	447,000	457,000	449,000	444,000	476,000	462,000	425,000	421,000	388,000	401,000	386,000	377,000	373,000	282,000	442,000	282,000	267,000	190,000	95,000	85,000	86,713	65,549	46,918	40,503
amortization of discounts for credit facility	534,000	512,000	508,000	581,000
amortization of discounts for convertible notes	80,000	79,000	79,000	77,000	77,000	76,000
accretion of discount to development liability			0	0	2,870,000	6,066,000	6,505,000	6,413,000	6,445,000	6,633,000	6,864,000	6,717,000	6,623,000	6,713,000
changes in operating assets and liabilities:
accounts receivable	21,118,000	29,680,000	14,085,000	25,421,000	-36,575,000	-61,415,000	-37,173,000	-58,356,000	-79,408,000	-23,778,000	365,000	-574,000	-1,189,000	3,773,000	-7,485,000	-1,899,000
inventory	-26,008,000	13,997,000	10,021,000	8,655,000	-14,510,000	-14,921,000	-47,816,000	4,671,000	-17,646,000	144,000	-25,961,000	-11,302,000	-15,601,000	-16,533,000	-14,640,000	2,054,000
prepaid assets	7,953,000	-18,726,000	5,398,000	5,190,000	14,170,000	-4,338,000	5,811,000	-10,216,000	2,642,000	-107,000	-5,987,000	-8,882,000	3,056,000	334,000	-7,625,000	1,611,000	-1,654,000	-5,819,000	235,000	6,626,000	4,881,000	-3,004,000	-5,059,719	-765,742	6,532,304	3,824,196	-7,478,756	-5,998,668	-2,735,685	-3,062,009
other current assets	-6,838,000	-1,307,000	142,000	612,000	-658,000	10,697,000	8,262,000	-3,865,000	7,538,000	2,308,000	-12,521,000	3,232,000	44,537,000	-2,312,000	-47,605,000	10,988,000	-69,000	-4,242,000	-25,657,000	197,000	-153,000	-671,000	1,171,628	2,155,786	-3,064,915	24,854	-296,210	-20,279	195,354	-188,226	1,936,041
other assets	61,000	198,000	786,000	225,000	-404,000	98,000	-3,111,000	-166,000	8,000	14,969,000	1,605,000	128,000	123,000	15,634,000	-8,826,000	-6,714,000	-9,188,000	11,946,000	-17,341,000	-1,000	-58,000	-460,000	-202,771	-28,952	-45,141	-45,925	-881,359				-7,800
right-of-use assets and lease liabilities	215,000	7,000	-270,000	164,000	-55,000	-116,000
accounts payable	-1,045,000	16,711,000	1,488,000	-1,158,000	11,489,000	-10,730,000	19,620,000	-9,601,000	-3,995,000	-5,854,000	23,126,000	-7,028,000	8,962,000	-6,371,000	13,700,000	83,000	874,000	-4,170,000	-2,446,000	792,000	6,837,000	-5,237,000	-3,433,391	-2,008,290	1,894,386	1,906,521	4,792,625	325,080	547,959	921,805	-521,548
accrued expenses	22,883,000	-30,156,000			22,022,000	-26,330,000	11,851,000	20,034,000	26,536,000	-23,471,000	14,952,000	-3,977,000	-20,939,000	3,652,000	31,700,000	-64,611,000	65,321,000	-42,802,000	50,999,000	13,617,000	421,000	-9,991,000	24,908,739	10,145,204	12,635,167	2,764,408	-5,461,504	5,465,051	2,411,377	-180,904	-46,180
deferred revenue				0	-1,657,000	3,560,000
net cash from operating activities	4,445,000	-53,410,000	19,360,000	34,096,000	-8,339,000	-132,983,000	-97,875,000	-169,085,000	-150,155,000	-177,620,000	-140,744,000	-154,417,000	-107,024,000	-111,560,000	-112,499,000	-168,625,000	-128,688,000	-153,314,000	141,979,000	-99,824,000	-94,294,000	-108,349,000	-82,071,683	-53,597,640	-39,905,638	-35,560,484	-44,478,223	-33,132,448	-30,694,877	-22,935,249	-15,532,804
capex	-49,000	-8,000	-20,000	0	-90,000	-293,000	-95,000	-47,000	-372,000	-259,000	-851,000	-196,000	-391,000	-86,000	-19,000	-352,000	-248,000	-484,000	-711,000	-3,738,000	-538,000	-435,000	-155,786	-470,047	-192,378	-875,111	0	0	0	0	0
free cash flows	4,396,000	-53,418,000	19,340,000	34,096,000	-8,429,000	-133,276,000	-97,970,000	-169,132,000	-150,527,000	-177,879,000	-141,595,000	-154,613,000	-107,415,000	-111,646,000	-112,518,000	-168,977,000	-128,936,000	-153,798,000	141,268,000	-103,562,000	-94,832,000	-108,784,000	-82,227,469	-54,067,687	-40,098,016	-36,435,595	-44,478,223	-33,132,448	-30,694,877	-22,935,249	-15,532,804
investing activities
purchase of property and equipment	-49,000	-8,000	-20,000	0	-90,000	-293,000	-95,000	-47,000	-372,000	-259,000	-851,000	-196,000	-391,000	-86,000	-19,000	-352,000	-248,000	-484,000	-711,000	-3,738,000	-538,000	-435,000	-155,786	-470,047	-192,378	-875,111
net cash from investing activities	-49,000	-8,000	-20,000	0	-90,000	-293,000	4,000	-47,000	-372,000	-259,000	124,129,000	124,784,000	82,929,000	-271,949,000	84,980,000	179,649,000	129,752,000	-146,765,000	-91,000	198,763,000	-287,807,000	-227,854,000	-155,786	-470,047	-192,378	-875,111
financing activities
proceeds from credit facility			0	0
payment of issuance cost for credit facility			-5,625,000	0
repayment of development liability			0	0
proceeds from settlement of capped call			0	0	0	98,763,000
proceeds from exercise of stock options	4,367,000	281,000	321,000	2,556,000	1,962,000	9,477,000	25,465,000	5,757,000	22,334,000	17,718,000		10,639,000	4,770,000	4,000,000		2,481,000	7,062,000	2,588,000		1,126,000	1,355,000	1,674,000		929,710	1,262,162	192,005		114,989	275,749	225,361
proceeds from issuance of common stock under employee stock purchase plan
payments of employee tax withholding related to equity-based compensation	0	-7,000	-15,000	-14,000	0	-28,000			-28,000	-10,999,000	-1,727,000	-1,003,000	-536,000	-2,416,000	-237,000	-361,000	-234,000	-956,000
net cash from financing activities	6,558,000	274,000	-4,000,000	2,542,000	42,487,000	108,212,000	-3,913,000	5,746,000	1,560,000	391,106,000	-15,946,000	9,636,000	-4,735,000	376,704,000	383,958,000	2,120,000	4,526,000	1,632,000	6,317,000	926,000	281,668,000	403,267,000	209,610	198,949,710	40,963,913	148,418,251	115,657	-38,434	131,603,440	222,697	178,040,485
effect of exchange rate changes on cash, cash equivalents and restricted cash	685,000	359,000	-965,000	173,000	342,000	-209,000		-458,000	-47,000	56,000		-310,000	-429,000	64,000		-172,000	-241,000	-1,611,000		-1,646,000	132,000	-152,000
net (decrease)/ increase in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash at beginning of period	0	412,612,000	0	0	0	352,299,000	-1,000	0	0	553,075,000	0	0	0	641,755,000	0	0	0	567,045,000	0	0	0	351,985,000
cash, cash equivalents and restricted cash at end of period	11,639,000	359,827,000	14,375,000	36,811,000	34,400,000	327,026,000	-101,201,000	-163,844,000	-149,014,000	766,358,000	-32,374,000	-20,307,000	-29,259,000	635,014,000	356,447,000	12,972,000	5,349,000	266,987,000	150,230,000	98,219,000	-100,301,000	418,897,000
reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
cash and cash equivalents	11,643,000	358,393,000		36,777,000	34,164,000	325,923,000		-163,845,000	-148,824,000	765,083,000		-20,300,000	-28,967,000	633,456,000		12,981,000	5,329,000	265,435,000		98,212,000	-100,533,000	417,881,000
restricted cash	-4,000	1,434,000		34,000	236,000	1,103,000		1,000	-190,000	1,275,000		-7,000	-292,000	1,558,000		-9,000	20,000	1,552,000		7,000	232,000	1,016,000
total cash, cash equivalents, and restricted cash	11,639,000	359,827,000		36,811,000	34,400,000	327,026,000		-163,844,000	-149,014,000	766,358,000		-20,307,000	-29,259,000	635,014,000		12,972,000	5,349,000	266,987,000		98,219,000	-100,301,000	418,897,000
supplemental disclosures
cash paid for interest	0	11,092,000		12,497,000	5,306,000	1,643,000		1,643,000	0	1,643,000		1,643,000	0	3,360,000		3,372,000	0	6,893,000		9,100,000	0	3,829,000	28,383	230,521	140,000	588,473	477,639
cash paid for income taxes	666,000	141,000						194,000	134,000	250,000		0
proceeds from income tax refunds net of income taxes paid					-138,000	257,000
net decrease in cash, cash equivalents and restricted cash		-52,785,000										-20,307,000
loss on conversion of debt											0				0	61,102,000	0	39,487,000
loss on disposal of fixed assets							-32,000	133,000	0	19,000
forfeiture of accrued interest in exchange of convertible notes											0				0	2,503,000	0	1,668,000
accrued expenses and other liabilities			-1,382,000
proceeds from sale of fixed assets
purchase of available-for-sale securities											0	0	0	-331,863,000	-1,000	1,000	0	-171,281,000	-311,880,000	1,000	-339,769,000	-227,419,000
proceeds from maturity of available-for-sale securities											124,980,000	124,980,000	83,320,000	60,000,000	85,000,000	180,000,000	130,000,000	25,000,000	312,500,000	202,500,000
proceeds from issuance of common stock, net of issuance costs								0			0	0	0	380,120,000					0	0	-170,000	381,593,000	-658,152	0	-22,740	110,262,000	0	-130,997
proceeds from issuance of common stock, pre-funded warrant offering, net of issuance costs
payments for development liability							-31,000,000	0			-18,000,000	0	-11,500,000	-5,000,000
proceeds from issuance of common stock under employee share purchase plan			1,319,000	0			1,624,000	0			1,707,000	0			1,272,000	0			1,054,000	0
net increase in cash, cash equivalents and restricted cash			14,375,000	36,811,000	34,400,000	-25,273,000		-163,844,000	-149,014,000	213,283,000				-6,741,000		12,972,000	5,349,000	-300,058,000		98,219,000	-100,301,000	66,912,000
proceeds from issuance of common stock and pre-funded warrant offering, net of issuance costs										384,387,000
issuance costs for credit facility incurred but not yet paid
income from remeasurement of development derivative liability															55,192,000	4,219,000	21,180,000	17,084,000	40,090,000	-2,697,000	-2,770,000	68,406,000	4,736,000	263,000	9,104,000	736,000
amortization of right of use assets
amortization of discounts for convertible notes, net of financing costs							75,000	75,000	74,000	73,000	73,000	96,000	146,000	144,000	143,000	142,000			5,060,000	4,928,000	3,554,000	1,994,000
payments for development derivative liability
effect of exchange rate changes on cash and cash equivalents																							8,300	-15,948	15,966	-3,616	-10,586
net increase in cash and cash equivalents																							-82,009,559	144,866,075	881,863	111,979,040	-44,373,152				162,507,681
amortization of right-of-use assets								-57,000	-15,000	-22,000		-44,000	-44,000	-17,000		-8,000	6,000	112,000		125,000	27,000	57,000		77,793	76,103	72,725
other liabilities												367,000	363,000	1,208,000									-250,000	0	15,067	76,150
payment of employee tax withholding related to equity-based compensation
convertible notes exchanged for common stock
(payments for)/proceeds from development derivative liability
payments for capped call transactions and associated costs																			0	0			0
proceeds from issuance of convertible notes, net of issuance costs																			0	-200,000			-487,762
proceeds from exercise of stock options and warrants
net decrease in cash and cash equivalents																													100,908,563	-22,712,552
supplemental disclosure of financing activities
loss on early extinguishment of debt																							0	293,083	0	1,208,132
amortization of debt discounts																		360,000					0
amortization of term loan facility discounts																							0
repayment of promissory note																							0
repayment of term loan facility																							0	0	0	-21,701,292
proceeds from / (payments for) development derivative liability																0
2019 convertible notes exchanged for common stock																	0	126,129,000
proceeds from development derivative liability																			0	0	0	20,000,000	0	20,000,000	40,000,000	60,000,000
non-cash lease expense
amortization of discounts for promissory note
deferred issuance costs																								0	-275,509	-334,462	4,246			-2,664
issuance of series e convertible preferred stock, net of issuance costs																															0
proceeds from issuance of term loan, net of issuance costs
proceeds from issuance of promissory note, net of issuance costs
proceeds from issuance of stock options and warrants
cash and cash equivalents at beginning of period																							0	0	0	176,267,666	0	0	0	175,643,529
cash and cash equivalents at end of period																							-82,009,559	144,866,075	881,863	288,246,706	-44,373,152	-33,198,722	100,908,563	152,930,977
supplemental disclosure of non-cash financing activities
conversion of convertible preferred stock to common stock
equity component of convertible notes
amortization of deferred financing costs
accretion of discounts for promissory note																									19,438	18,777	18,744
accretion of discounts for term loan facility																									0	104,172	118,955
refundable research and development credit																									-212,022	-275,218	-142,453	543,082	-168,431	-531,204	946,204
(gain)/income from remeasurement of fair value of warrants
issuance of series d convertible preferred stock, net of issuance costs
proceeds from issuance of promissory note payable to an affiliate of stockholder
proceeds from the issuance of common stock warrants
conversion of series a convertible preferred stock
conversion of series b convertible preferred stock
conversion of series c convertible preferred stock
conversion of series d convertible preferred stock
shares reserved under 2010 equity incentive plan
shares reserved under 2017 equity incentive plan
shares reserved under 2017 employee stock purchase plan
common stock warrants
total																											-533,869	5,444,462	2,411,377	2,709,801	5,046,442
income from remeasurement of fair value of warrants																												0	0	5,708
unrealized foreign currency loss
proceeds for issuance of series e convertible preferred stock, net of issuance costs
supplemental cash flow information:
accrued research and development																												4,376,707	1,620,430	1,857,970
accrued payroll liabilities																												887,926	758,733	703,186
other																												179,829	32,214	148,645
accretion of discounts																													17,675	17,073
amortization of term loan facility
amortization																														208,624
non-cash acquisition of in-process research and development
issuance of series c convertible preferred stock, net of issuance costs
cash and cash equivalents beginning of period
cash and cash equivalents end of period

We provide you with 20 years of cash flow statements for Apellis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Apellis Pharmaceuticals stock. Explore the full financial landscape of Apellis Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Apellis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.